» Articles » PMID: 36430305

MiRNAs in Regulation of Tumor Microenvironment, Chemotherapy Resistance, Immunotherapy Modulation and MiRNA Therapeutics in Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Nov 26
PMID 36430305
Authors
Affiliations
Soon will be listed here.
Abstract

miRNAs are 20-22 long nucleotide non-coding ribonucleic acid molecules critical to the modulation of molecular pathways. Immune evasion and the establishment of a suitable tumor microenvironment are two major contributors that support tumor invasion and metastasis. Tumorigenic miRNAs support these two hallmarks by desensitizing important tumor-sensitive regulatory cells such as dendritic cells, M1 macrophages, and T helper cells towards tumors while supporting infiltration and proliferation of immune cells like Treg cells, tumor-associated M2 macrophages that promote self-tolerance and chronic inflammation. miRNAs have a significant role in enhancing the efficacies of immunotherapy treatments like checkpoint blockade therapy, adoptive T cell therapy, and oncolytic virotherapy in cancer. A clear understanding of the role of miRNA can help scientists to formulate better-targeted treatment modalities. miRNA therapeutics have emerged as diverse class of nucleic acid-based molecules that can suppress oncogenic miRNAs and promote the expression of tumor suppressor miRNAs.

Citing Articles

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z Front Cell Dev Biol. 2025; 12:1499111.

PMID: 39882259 PMC: 11774998. DOI: 10.3389/fcell.2024.1499111.


Upregulation of miRNA-450b-5p targets ACTB to affect drug resistance and prognosis of ovarian cancer via the PI3K/Akt signaling pathway.

Xie S, Su Y, Zhang J, Yin F, Liu X Transl Cancer Res. 2024; 13(9):4800-4812.

PMID: 39430863 PMC: 11483453. DOI: 10.21037/tcr-24-292.


MicroRNA-34a negatively regulates Netrin1 and mediates MEK/ERK pathway to regulate chemosensitivity of gastric cancer cells.

Liu H, Wang L Discov Oncol. 2024; 15(1):563.

PMID: 39404782 PMC: 11480279. DOI: 10.1007/s12672-024-01451-w.


Regulatory effect of N6-methyladenosine on tumor angiogenesis.

YuYan , Yuan E Front Immunol. 2024; 15:1453774.

PMID: 39295872 PMC: 11408240. DOI: 10.3389/fimmu.2024.1453774.


Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma.

Wang C, Zhang Y, Kong W, Rong X, Zhong Z, Jiang L Int J Nanomedicine. 2024; 19:8641-8660.

PMID: 39188861 PMC: 11346496. DOI: 10.2147/IJN.S471900.


References
1.
Ji Y, Hocker J, Gattinoni L . Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol. 2015; 28(1):45-53. PMC: 4862908. DOI: 10.1016/j.smim.2015.11.006. View

2.
Okamoto K, Miyoshi K, Murawaki Y . miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013; 8(10):e77623. PMC: 3798426. DOI: 10.1371/journal.pone.0077623. View

3.
Tronik-Le Roux D, Daouya M, Jacquier A, Schenowitz C, Desgrandchamps F, Rouas-Freiss N . The HLA-G immune checkpoint: a new immuno-stimulatory role for the α1-domain-deleted isoform. Cell Mol Life Sci. 2022; 79(6):310. PMC: 11072982. DOI: 10.1007/s00018-022-04359-2. View

4.
Suresh B, Li W, Zhang P, Wang K, Yildirim I, Parker C . A general fragment-based approach to identify and optimize bioactive ligands targeting RNA. Proc Natl Acad Sci U S A. 2020; 117(52):33197-33203. PMC: 7777249. DOI: 10.1073/pnas.2012217117. View

5.
Chen J, Chen Y, Chen Z . MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest. 2013; 31(1):17-23. DOI: 10.3109/07357907.2012.743557. View